A blood-based approach could enable personalized immunotherapy without the need for a tumor biopsy Cancer neoantigens and neoantigen-specific T…
featured news
An international team of scientists has launched a global roadmap for the delivery of advanced cancer treatments, paving the…
In the two decades since its official establishment in 2006, the Vall d’Hebron Institute of Oncology (VHIO) has established itself…
The Vall d’Hebron Institute of Oncology (VHIO) is launching VHIODivulga, a different, more accessible and engaging way of communicating the…
For the fourth consecutive year, VHIO is opening applications for its mentoring programme, VHIO4STEM. During the programme, 22 students in…
Results of final overall survival analysis from the global, randomized phase 3 MATTERHORN clinical trial show that adding perioperative durvalumab…
An international study led by VHIO within the ENIGMA consortium has analysed 166 variants in and around exon 18 of…
The European Society for Medical Oncology (ESMO) announced the professionals selected for its 2026 Fellowship Programme, including Maria Vieito and…
Published in The Lancet, results of the phase III LITESPARK-011 clinical trial point to the combination of belzutifan plus lenvatinib…
First results from the multicenter FUSOMAP project, led by VHIO, support the potential use of Fusobacterium as a prognostic and…
